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Gender Differences in Anxiety and Concerns about the
Cardioverter Defibrillator
HELLE SPINDLER, PH.D.,* JENS B. JOHANSEN, M.D., PH.D.,† KIRSTEN ANDERSEN,†
PETER MORTENSEN, M.D.,† and SUSANNE S. PEDERSEN, PH.D.‡
From the *Department of Psychology, Aarhus University, Aarhus, Denmark; †Department of Cardiology, Aarhus
University Hospital, Aarhus, Denmark; and ‡CoRPS—Center of Research on Psychology in Somatic diseases,
Tilburg University, Tilburg, The Netherlands
Background: Little is known about gender differences in the response to implantable cardioverter
defibrillator (ICD) therapy. We compared female and male ICD patients on anxiety, depression, health-
related quality of life (HRQL), ICD concerns, and ICD acceptance.
Methods: A cohort of consecutive, surviving patients (n = 535; mean age = 61.5 ± 14.4, 81.9% male)
implanted with an ICD between 1989 and 2006 completed the Hospital Anxiety and Depression Scale, the
Short-Form Health Survey (SF-36), the ICD concerns questionnaire, and the Florida Patient Acceptance
Survey.
Results: High levels of anxiety (52% vs 34%, P < 0.001) and ICD concerns (34% vs 16%, P = 0.001) were
more prevalent in women than men, whereas no significant differences were found on depression and
device acceptance (Ps > 0.05). Women were more anxious (odds ratio [OR]: 2.60 [95% confidence interval
(CI): 1.46–4.64], P < 0.01) and had more ICD concerns (OR: 1.81 [95% CI: 1.09–3.00], P < 0.05) than men,
adjusting for demographic and clinical characteristics. Those ICD patients experiencing shocks were also
more anxious (OR: 2.02 [95% CI: 1.20–3.42], P < 0.01) and had higher levels of ICD concerns (OR: 2.70
[95% CI: 1.76–4.16], P < 0.01). In multivariable analysis of variance, significant gender differences were
found for only three of the eight subscales of the SF-36 (the physical social functioning and the mental
health subscale), with women reporting poorer HRQL on all three subscales.
Conclusions: Women were more prone to experience anxiety and ICD concerns compared to men
regardless of whether they had experienced shocks. In clinical practice, female ICD patients should be
closely monitored, and if warranted offered psychosocial intervention, as increased anxiety has been
shown to precipitate arrhythmic events in defibrillator patients. (PACE 2009; 32:614–621)
cardioverter defibrillator, gender, anxiety, ICD concerns
Introduction
The medical benefits of implantable car-
dioverter defibrillator (ICD) therapy are well es-
tablished.1–3 Nevertheless, there is a considerable
gap in the implantation rate of the ICD between
women and men, with women being less likely to
receive an ICD.4–7 Although gender differences in
cardiac electrophysiology and arrhythmias have
been identified,8 the survival benefits of ICD ther-
apy are similar in men and women.4,9 The reasons
for the disparity in implantation rates are largely
unknown,10 with differences in age, patient pref-
erences (e.g., refusal rates), and comorbid con-
ditions between men and women being unlikely
explanations.4
ICD implantation and therapy may be associ-
ated with both medical and psychological compli-
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cations,2,11 including increased anxiety, depres-
sion, avoidance behaviors, and impaired health-
related quality of life (HRQL),12 although only a
subgroup of patients tend to experience difficul-
ties following implantation.12 Since women gen-
erally are more likely to be anxious, depressed,
and to report poorer HRQL compared to men,13,14
female ICD patients may also be at higher risk of
these outcomes than male patients.
Paradoxically, little is known about gender
differences in these patient-centered outcomes in
patients treated with ICD therapy, with available
studies being based on a relatively small num-
ber of women. Two studies found no gender dif-
ferences in anxiety and depression,15,16 whereas
a third study found female gender and shocks
to be associated with both anxiety and depres-
sion.17 In relation to HRQL, one study found that
women report lower functional status compared
to men.16 Another study showed women to have
lower scores on the SF-36 role emotional function-
ing subscale at 3 months postimplant compared to
men, but this difference was no longer significant
at 12 months.18 In contrast, women consistently re-
ported better general health as compared to men.18
C©2009, The Authors. Journal compilation C©2009 Wiley Periodicals, Inc.
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The aims of the current study were to exam-
ine (1) whether women are at a greater risk of
increased anxiety, depression, ICD concerns, and
lower device acceptance, and (2) whether women
have poorer HRQL compared to men, adjusting for
demographic and clinical characteristics.
Method
Patients and Study Design
ICD patients implanted with an ICD at Aarhus
University Hospital (Skejby), Denmark, since 1989
and still alive on November 1, 2006, were included
in the current study. ICD patients implanted with
a first ICD within the last 3 months were excluded.
Generally, prophylactic implantation was not im-
plemented in Denmark prior to 2007; therefore,
the majority of patients (94.8%) had a secondary
indication for ICD. The design of the study has
been previously published.19 Of 723 eligible pa-
tients, 624 (86%) participated.19 Cases without
any scores on individual items of the psychologi-
cal scales used in the current study were excluded
from statistical analysis (n = 75). For the remain-
ing cases, missing data were imputed using the
expectation-maximization (EM) algorithm, which
has been demonstrated to be an effective method of
dealing with missing data.20 Hence, for the current
study analyses were based on 535 patients (81.9%
male; mean age = 61.5 ± 14.4 years; mean time
since first ICD implantation = 4.6 ± 3.2 years).
All surviving ICD patients received informa-
tion about the study by mail and were asked
to complete a self-report questionnaire contain-
ing questions on clinical data and standardized
and validated psychological questionnaires. Re-
minders, including a duplicate of the question-
naire, were mailed to nonresponders after 2 weeks.
The study was conducted in accordance with the
Helsinki Declaration.
Measures
Demographic and Clinical Variables
Demographic variables comprised gender,
age, and having a partner. Clinical variables in-
cluded etiology of heart disease (i.e., ischemic vs
nonischemic, with nonischemic defined as car-
diomyopathy [hypertrophic, dilated, other], idio-
pathic ventricular fibrillation, arrythmogenic right
ventricular, congenital heart disease, congenital
long QT, valvular heart disease, or Brugada syn-
drome), symptomatic heart failure (HF), comor-
bidity, device-related complications, time since
first implantation, and having experienced shocks
(shocks ≥1). Information on clinical variables was
retrieved from the patients’ medical records, the
Danish ICD Registry,21 and from purpose-designed
questions. All reoperations caused by device or
lead malfunctioning or infection, as registered by
the Danish ICD Registry,21 were considered as
complication to ICD therapy. Comorbidity (e.g.,
gait, diabetes, muscular dystrophy, stroke, can-
cer, pulmonary disease, and renal insufficiency)
and number of ICD shocks were based on self-
report. Symptomatic HF was determined using
the Minnesota Living with Heart Failure (MLHF)
questionnaire.22 The 21-item MLHF is a valid and
reliable, disease-specific measure of HRQL, with
items scored on a six-point Likert scale from 0
(no) to 5 (very much). The total MLHF score ranges
from 0 to 105, with a lower score indicating good
HRQL. Dichotomization was undertaken in order
to enhance the interpretation of the results in clin-
ical practice.23 A MLHF score above 40 represents
New York Heart Association (NYHA) classes III
and IV (i.e., symptomatic HF).24 The 75% upper
percentile in our data was 41 corresponding with
NYHA classes III and IV, and the cutoff of >40 on
the MLHF was used as a marker of symptomatic
HF.
Hospital Anxiety and Depression Scale C©
The HADS
C©
is a 14-item self-report measure,
consisting of two 7-item subscales measuring anxi-
ety and depressive symptoms.25 Responses are in-
dicated on a four-point Likert Scale from 0 to 3
(score range 0–21). The two subscales have been
shown to be internally consistent, as measured by
Cronbach’s α: HADS-A = 0.80; HADS-D = 0.81.26
In addition, a recent review of 15 studies showed
HADS to be a valid and reliable instrument, with
Cronbach’s α for HADS-A ranging from 0.68 to
0.93 and for HADS-D ranging from 0.67 to 0.90.27
This review also showed ≥8 on both subscales to
be an optimal cutoff point as an indication of likely
psychopathology, with sensitivity and specificity
ranging between 0.70 and 0.90 for most reviewed
studies.27 In the current study, this cutoff was used
to dichotomize symptoms into present or nonpre-
sent to obtain the best clinical indication of anxi-
ety or depressive symptoms. The HADS has been
used in both cardiac and noncardiac populations,
and is appropriate to use in patients with somatic
disease, as it is devoid of somatic symptoms.27
ICD Concerns
Device-related concerns were assessed with
the ICD Concerns questionnaire (ICDC). In the cur-
rent study, we used an adapted and abbreviated
C©
Munksgaard International Publishers Ltd, Copenhagen,
1983. Permission to use HADS can be obtained through Nfer-
Nelson Publishing Company Ltd., The Chiswick Centre, 414
Chiswick High Road, London W4 5TF, UK. All rights reserved.
NferNelson is a division of Granada Learning Ltd., part of
Granada plc.
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version of the original 20-item questionnaire,28 the
ICDC-8.29 The internal consistency of the abbrevi-
ated version is good (α = 0.91),29 which was con-
firmed in the current study (α = 0.94). The ICDC-8
consists of eight items (i.e., “I am worried about
my ICD firing”; “I am worried about having no
warning my ICD will fire”) rated on a five-point
Likert scale from 0 (not at all) to 4 (very much
so), with a higher score reflecting a higher level of
device-related concerns.
Acceptance of the Cardioverter Defibrillator
The 18-item Florida Patient Acceptance Sur-
vey (FPAS) is a disease-specific measure assess-
ing device acceptance.30 Items are rated on a five-
point Likert scale from 0 (strongly disagree) to 5
(strongly agree), with a higher score indicating
better acceptance. Only 15 of the 18 items con-
tribute to the four subscales: (1) Return to Func-
tion, (2) Device-Related Distress, (3) Positive Ap-
praisal, and (4) Body Image Concerns as well as the
total score.30 The convergent, divergent, and dis-
criminant validity of the FPAS are good, and the
scale has been shown to be internally consistent,
as indicated by Cronbach’s α ranging from 0.74 to
0.83.30 The validity and reliability of the Danish
version of the FPAS has recently been confirmed
in the present cohort of ICD patients.31
Health-Related Quality of Life
HRQL was assessed with the 36-item Short-
Form Health Survey (SF-36), which is a generic
measure of HRQL.32,33 The SF-36 consists of 36
items grouped into eight subscales: physical func-
tioning, role physical functioning (measures the
impact of physical health on work or other daily
activities), role emotional functioning (measures
the impact of emotional problems on work or
other daily activities), mental health, vitality, so-
cial functioning, bodily pain, and general health
(score range/subscale: 0–100), with higher scores
indicating good HRQL or the absence of pain. The
SF-36 has proven to be a valid and reliable instru-
ment, with Cronbach’s α for the various subscales
ranging from 0.78 (general health) to 0.93 (physi-
cal functioning).32
Statistical Analyses
Prior to statistical analyses, scores on the
FPAS were dichotomized using the lowest ter-
tile to indicate poor device acceptance (i.e., FPAS
< = 73).31 Likewise, scores on the ICDC-8 were
dichotomized using the highest tertile to indi-
cate a high level of device-related concerns (i.e.,
ICDC > = 74).34 Discrete variables were com-
pared using the χ2 test (Fisher’s exact test when
appropriate) and continuous variables with Stu-
dent’s t-test. Multivariable analysis of variance
(MANOVA) was used to examine the influence
of gender on HRQL, as measured with the SF-36
subscales. Multivariable logistic regression analy-
ses were used to determine whether gender was
independently associated with anxiety, depres-
sion, device acceptance, and device-related con-
cerns adjusting for age, partner, time since first im-
plantation, coronary artery disease etiology, symp-
tomatic HF, comorbidity, device-related compli-
cations, and one or more shocks (≥1). Based on
these results, we conducted two-factor analyses
of variance (ANOVA) with gender and shocks as
independent variables and anxiety and device-
related concerns as the dependent variables. In
MANOVA, results for the SF-36 were adjusted
for age, partner, time since first implant, coro-
nary artery disease etiology, symptomatic HF,
comorbidity, device-related complications, and
shocks (≥1). All the covariates entered in adjusted
analyses were selected either on the basis of the
literature or results of univariable analysis. A P-
value of 0.05 was chosen to indicate statistical sig-
nificance, and all tests were two tailed. Odds ratios
(OR) with their corresponding 95% confidence in-
tervals (CI) are reported for the logistic regression
analyses. All analyses were performed using SPSS
13.0 for Windows (SPSS Inc., Chicago, IL, USA).
Results
There were no systematic differences (all P-
values >0.05) between ICD patients included in
the analysis (n = 535) and those excluded (non-
responders and responders with incomplete psy-
chological data [n = 194] on gender, age, coro-
nary artery disease etiology, and device-related
complications [results not shown]). However, ICD
patients included in the study were more likely
to have had their ICD for a shorter period of
time (4.70 ± 3.24 vs 5.35 ± 3.61 years, t = 2.33,
P = 0.02).
Patient Characteristics
Patient characteristics for the total group and
stratified by gender are displayed in Table I. The
total group comprised 438 males and 97 females.
Women were younger (55.22 ± 15.2 vs 62.94 ±
13.9, P < 0.001) and less likely to have a partner
compared to men (66% vs 80%, P = 0.002). In
terms of their clinical profile, women were less
likely to have ischemic heart disease (37% vs 66%,
P < 0.001) but were more likely to suffer from
comorbid conditions (35% vs 19%, P < 0.001).
Gender Differences on Anxiety, Depression,
Device Concerns, and Acceptance
Descriptive characteristics for each gender
and the total group are presented in Table I. ICD
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Table I.
Demographic, Clinical, Psychological Characteristics, and Health-Related Quality of Life for the Total Group and Stratified
by Gender
Female (n = 97) Male (n = 438) Total (n = 535) P Value
Demographic
Age, mean (SD) 55.22 ± 15.2 62.94 ± 13.9 61.54 ± 14.4 <0.001*
Cohabiting, n (%) 63 (66) 347 (80) 410 (78) 0.002*
Clinical
Ischemic etiology, n (%) 36 (37) 291 (66) 327 (61) <0.001*
Complications, n (%) 6 (6) 37 (8) 43 (8) 0.458
Symptomatic HF, n (%) 23 (24) 106 (24) 129 (24) 0.919
Shocks, n (%) 40 (41) 185 (43) 225 (43) 0.775
Time since first implant, mean (SD) 4.83 ± 3.2 4.67 ± 3.2 4.70 ± 3.2 0.656
Comorbidity, n (%) 34 (35) 82 (19) 116 (22) <0.001*
Psychological
ICD concerns, mean (SD) 10.34 ± 9.4 6.89 ± 7.7 7.72 ± 8.1 0.001*
Device acceptance, mean (SD) 77.64 ± 18.0 78.13 ± 16.8 78.04 ± 17.0 0.930
Anxiety, mean (SD) 5.89 ± 4.6 3.92 ± 3.8 4.27 ± 4.0 <0.001*
Depression, mean (SD) 3.42 ± 3.3 3.22 ± 3.3 3.3 ± 3.3 0.960
Health-related quality of life4
Physical functioning, mean (SD) 64.02 ± 29.9 67.10 ± 26.1 66.54 ± 26.8 0.307
Social functioning, mean (SD) 79.25 ± 24.1 84.73 ± 22.6 83.74 ± 23.0 0.033*
Role physical functioning, mean (SD) 52.84 ± 44.2 47.77 ± 43.3 48.69 ± 43.5 0.300
Role emotional functioning, mean (SD) 67.01 ± 40.4 67.58 ± 39.2 67.48 ± 39.4 0.898
Mental health, mean (SD) 74.19 ± 20.2 79.83 ± 17.8 78.80 ± 18.4 0.006*
Vitality, mean (SD) 57.16 ± 25.8 60.14 ± 25.2 59.60 ± 25.3 0.295
Bodily pain, mean (SD) 74.39 ± 29.3 79.17 ± 24.9 78.30 ± 25.8 0.099
General health, mean (SD) 59.65 ± 24.7 58.61 ± 24.3 58.80 ± 24.3 0.704
*P < 0.05.
concerns (34% vs 16%, P = 0.001) and anxiety
(52% vs 34%, P < 0.001) were more prevalent
in women than in men, and remained so when
adjusting for age, partner, time since first im-
Table II.
Independent Associates of Anxiety, Depression, ICD Concerns, and Device Acceptance
Anxiety Depression ICD Concerns Device acceptance
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Female gender 2.60 (1.46–4.64)** 1.09 (0.48–2.46) 1.81 (1.09–3.00)* 1.01 (0.56–1.78)
Older age 0.99 (0.97–1.01) 1.03 (1.00–1.05) 0.98 (0.96–1.00)* 1.02 (1.00–1.04)*
Cohabiting 1.16 (0.65–2.08) 0.87 (0.43–1.75) 0.76 (0.48–1.21) 0.56 (0.35–0.92)*
Nonischemic etiology 1.55 (0.89–2.72) 1.44 (0.74–2.78) 1.17 (0.74–1.85) 1.24 (0.76–2.01)
Symtomatic HF 6.23 (3.68–10.55)** 9.07 (4.95–16.59)** 3.96 (2.52–6.25)** 6.75 (4.26–10.69)**
Complications 0.92 (0.38–2.24) 0.54 (0.17–1.78) 1.13 (0.55–2.34) 1.06 (0.48–2.35)
Time since first implant 1.01 (0.93–1.10) 1.00 (0.90–1.10) 0.96 (0.89–1.02) 0.95 (0.88–1.02)
Shocks 2.02 (1.20–3.42)** 1.51 (0.80–2.87) 2.70 (1.76–4.16)** 1.40 (0.89–2.21)
Comorbidity 0.99 (0.56–1.75) 0.66 (0.32–1.36) 1.05 (0.65–1.70) 0.98 (0.59–1.62)
*P < 0.05; **P < 0.01.
plantation, coronary artery disease etiology, symp-
tomatic HF, comorbidity, device-related complica-
tions, and one or more shocks (≥1) (see Table II).
There were no gender differences on depression
PACE, Vol. 32 May 2009 617
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Figure 1. Prevalence of anxiety and ICD concerns strat-
ified by gender and shocks. a A cutoff of ≥8 on the HADS
anxiety subscale was used to indicate clinically signif-
icant levels of anxiety.27 b Scores on the ICDC-8 were
dichotomized using the highest tertile to indicate a high
level of device-related concerns (i.e., ICDC > = 74).34
and device acceptance (see Table I), nor on
the device acceptance subscales return to func-
tion, device-related distress, positive appraisal,
and body image concerns (results not shown).
Table II presents the independent associates of
the psychological endpoints: anxiety, depression,
device concerns, and device acceptance. Of note,
symptomatic HF was associated with all psycho-
logical endpoints, whereas having experienced
shocks was only associated with anxiety and ICD
concerns.
Given that statistically significant differences
were found between women and men on anxiety
and ICD concerns, we further examined whether
these differences were associated with shocks. A
two-factor ANOVA using gender and shocks as
fixed factors only found a main effect for gender
on anxiety (F1 = 18.29, P < 0.001), although there
was a trend for the interaction effect gender by
shocks (F1 = 3.20, P = 0.074). For ICD concerns
there was a significant main effect for both gender
(F1 = 16.66, P < 0.001) and shocks (F1 = 25.66,
P < 0.001) whereas the interaction effect gender by
shocks failed to reach significance. This indicates
that females experience high levels of anxiety re-
gardless of shocks, whereas gender differences on
ICD concerns are determined by both gender and
shocks, with females having experienced shocks
reporting the highest level of device-related con-
cerns (see Fig. 1).
Gender Differences on HRQL
MANOVA showed women to have impaired
HRQL on the social functioning and mental health
subscales of the SF-36 (see Table I). When ad-
justing for age, partner, time since first implant,
coronary artery disease etiology, symptomatic HF,
comorbidity, device-related complications, and
shocks (≥1), female gender was associated with
impaired HRQL on the physical functioning, the
social functioning, and the mental health sub-
scales (see Table III). Table III presents all indepen-
dent associates of HRQL. Of note, symptomatic HF
was associated with impaired HRQL on all sub-
scales, whereas shocks were not associated with
any of the HRQL subscales.
Discussion
The results of the current study showed
that female patients with an ICD were more
likely to be anxious, and report high levels
of ICD concerns and impaired HRQL on the
mental health, physical, and social functioning
subscales of the SF-36 than male patients. No
statistically significant differences were found be-
tween women and men on depression and device
acceptance. In adjusted analysis, symptomatic
HF was generally associated with worse patient-
centered outcomes, including more anxiety,
depression, and ICD concerns, poor device accep-
tance, and impaired HRQL irrespective of gen-
der. Furthermore, having received one or more
shocks was another significant associate of in-
creased anxiety and ICD concerns. Additional
analyses examining the impact of both gender
and shocks showed that female patients had
the highest prevalence of anxiety irrespective
of shocks, whereas females having experienced
shocks showed the highest prevalence of ICD
concerns.
Bilge and colleagues also found female gen-
der to be associated with increased anxiety
and depression,17 whereas three other studies
found no gender differences on anxiety or de-
pression.15,16,35 Examining device-related fears,
618 May 2009 PACE, Vol. 32
GENDER DIFFERENCES IN ANXIETY
Table III.
Independent Associates of Health-Related Quality of Lifea
PF SF RP RE MH VT BP GH
SF-36 Subscales F1,512 F1,512 F1,512 F1,512 F1,512 F1,512 F1,512 F1,512
Female gender 5.22* 4.16* 0.02 0.82 6.74* 2.08 1.30 0.01
Older age 68.91** 0.84 37.02** 5.78* 0.05 2.46 12.78** 2.05
Cohabiting 4.58* 1.00 1.92 2.29 0.03 0.53 0.11 0.00
Nonischemic etiology 0.31 0.04 0.02 4.21* 0.42 0.43 5.97* 1.37
Symptomatic HF 248.76** 234.53** 111.34** 84.46** 109.86** 212.45** 129.65** 175.69**
Complications 1.06 0.26 4.15* 3.95* 0.02 3.48 0,00 0,05
Time since first implant 1.51 4.93* 3.23 1.57 1.60 4.38* 0.16 0.13
Shocks 1.12 0.53 0.54 0.05 3.76 1.16 1.01 0.42
Comorbidity 11.10** 5.43* 1.20 0.04 0.18 0.87 20.00** 10.32**
*P < 0.05; **P < 0.01.
aSF-36: PF = physical functioning; SF = social functioning; RP = role physical functioning; RE = role emotional functioning; MH =
mental health; VT = vitality; BP = bodily pain; GH = general health.
Sowell and colleagues found that female ICD pa-
tients reported more shock and death anxiety than
men.36 However, only one of these studies had a
relatively large sample size (n = 180),16 suggest-
ing that the majority of studies may not have been
sufficiently powered to adequately detect gender
differences if present. In the current study, the
sample size was large, and therefore, we were
able to adjust for several potential confounding
variables that may be associated with the patient-
centered outcomes examined. The choice of self-
report measure may be another reason for the in-
consistent results. Two studies used HADS as a
measure of anxiety and depression, but found in-
consistent results,17,35 whereas the two studies
using the Beck Depression Inventory and Spiel-
berger’s State and Trait Anxiety Inventory found
no differences.15,16
The current study extends previous research
by examining gender differences on the disease-
specific measures ICD concerns and device accep-
tance. Based on the literature, (i.e., Walker et al.14),
we expected gender differences with regard to de-
vice acceptance, especially on the subscale of body
image concerns; however, such differences could
not be detected in the current sample. Reasons for
this are unknown; however, a recent study of fe-
male ICD patients showed younger age to be asso-
ciated with more shock anxiety, death anxiety, and
body image concerns.37 In the current study, male
ICD patients had concerns about their body image
on par with women; however, older age showed
a small yet significant association with device ac-
ceptance in general, indicating that this associa-
tion is not gender- but age-specific. Another reason
could be that gender differences in concerns were
more readily reported as general concerns about
the ICD, since the current study showed women
to be more likely to display high levels of ICD
concerns. Of note, a previous study showed high
levels of ICD concerns to be associated with in-
creased anxiety and depression,29,34 but although
women experienced more anxiety and ICD con-
cerns, they reported accepting their device on par
with men. This is somewhat surprising, since a
previous study showed increased anxiety and de-
pression to be associated with less acceptance in
a sample of both genders.38 Taken together, this
indicates that further studies are warranted that
examine the influence of gender and age on psy-
chological distress, ICD concerns, and device ac-
ceptance, including analyses that are stratified by
gender.
Having experienced a shock was indepen-
dently associated with both anxiety and ICD con-
cerns. From a clinical point of view, this suggests
that it is important to screen for and address ICD
concerns and anxiety in those ICD patients whose
device have fired, in order to prevent the negative
impact of this experience. Furthermore, anxiety
has been shown to precipitate arrhythmic events,
making detection of increased anxiety an impor-
tant issue in ICD patients.39 The importance of this
may be even more relevant in women than men,
since both female gender and shocks were inde-
pendently associated with anxiety and ICD con-
cerns. Taken together, since women are generally
known to report more anxiety than men, this may
predispose them to experience more anxiety af-
ter ICD implantation, with ICD shocks possibly
PACE, Vol. 32 May 2009 619
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accentuating anxiety by increasing levels of ICD
concerns.
Our findings show that women experience
impaired physical and social functioning com-
pared to men. In addition, women experienced im-
paired HRQL on the mental health domain, which
is consistent with the fact that women in gen-
eral are more prone to experiencing anxiety and
depression than men.13,14 Although previous re-
search has shown lower functional status in fe-
male ICD recipients,16 this study did not use the
SF-36, and the current results are not consistent
with previous findings using the SF-36 showing
better general health in female ICD recipients.18
In sum, differences in research design (retrospec-
tive vs prospective), HRQL measure, sample size,
and the lack of control for demographic and clin-
ical variables in previous studies may account for
some of these inconsistencies.
Taken together, the current study suggests
that although psychosocial interventions target-
ing anxiety, ICD concerns, and HRQL are im-
portant to all ICD patients, women may have
different needs compared to men following ICD
implantation. Therefore, stratifying ICD rehabili-
tation by gender after implantation and especially
after experiencing shocks may assist in targeting
the specific needs of female ICD patients. A re-
cent study of female ICD patients showed that
younger age was associated with more shock anx-
iety, death anxiety, and body image concerns. In a
recent review on psychological interventions fol-
lowing ICD implantation, almost all trials showed
significantly reduced anxiety following interven-
tion,40 suggesting that such interventions may
be beneficial to the anxious and concerned ICD
patients.
The results of the current study should be
interpreted with some caution. First, the cross-
sectional design does not allow for the inference of
cause and effect. Second, information on anxiety
and depression were obtained by self-report rather
than diagnostic interview, although all question-
naires were standardized and validated. Third,
some clinical variables were obtained by self-
report, which may have resulted in bias (i.e., will-
ingness to report, retrieval bias, etc.). Fourth, data
may not have been missing at random; hence, the
assumptions for the imputation of missing data
may have been violated.
This study also has several strengths, includ-
ing the use of disease-specific questionnaires (i.e.,
the ICDC and the FPAS), the relatively high re-
sponse rate, and the large sample size, which en-
abled us to address the issue of gender differences
adequately.
In conclusion, in the current study female ICD
patients were more likely to experience anxiety,
high levels of ICD concerns, and impaired HRQL
compared to males, whereas no differences were
found on device acceptance and depression. The
risk of increased anxiety and ICD concerns was es-
pecially salient in female ICD patients who were
also shocked by the ICD. In clinical practice, fe-
male ICD patients should be closely monitored,
and if warranted offered psychosocial intervention
to avoid increasing the risk of arrhythmic events
associated with increased anxiety.39 Further stud-
ies are warranted to examine gender differences on
psychological distress, ICD concerns, and device
acceptance, as inconsistent findings in the litera-
ture may be attributable to methodological issues,
including insufficient power to reliably address
gender differences.
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